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The Use of High-Flow Nasal Oxygen in 
the ICU as a First-Line Therapy for Acute 
Hypoxemic Respiratory Failure Secondary to 
Coronavirus Disease 2019
Gregory McDonough, MD1; Phue Khaing, MD1,2; Taylor Treacy, BMSc3; Christopher McGrath, MD1,2;  
Erika J. Yoo, MD1,2
Objectives: Limited evidence is available regarding the role of high-
flow nasal oxygen in the management of acute hypoxemic respiratory 
failure secondary to coronavirus disease 2019. Our objective was to 
characterize outcomes associated with high-flow nasal oxygen use in 
critically ill adult patients with coronavirus disease 2019-associated 
acute hypoxemic respiratory failure.
Design: Observational cohort study between March 18, 2020, and 
June 3, 2020.
Setting: Nine ICUs at three university-affiliated hospitals in 
Philadelphia, PA.
Patients: Adult ICU patients with confirmed coronavirus disease 
2019 infection admitted with acute hypoxemic respiratory failure.
Interventions: None.
Measurements and Main Results: Of 266 coronavirus disease 
2019 ICU admissions during the study period, 124 (46.6%) 
received some form of noninvasive respiratory support. After 
exclusions, we analyzed 83 patients who were treated with high-
flow nasal oxygen as a first-line therapy at or near the time of ICU 
admission. Patients were predominantly male (63.9%). The most 
common comorbidity was hypertension (60.2%). Progression 
to invasive mechanical ventilation was common, occurring in 58 
patients (69.9%). Of these, 30 (51.7%) were intubated on the 
same day as ICU admission. As of June 30, 2020, hospital mortal-
ity rate was 32.9% and the median hospital length of stay was 15 
days. Among survivors, the most frequent discharge disposition 
was home (51.0%). In comparing patients who received high-flow 
nasal oxygen alone (n = 54) with those who received high-flow 
nasal oxygen in conjunction with noninvasive positive-pressure 
ventilation via face mask (n = 29), there were no differences in 
the rates of endotracheal intubation or other clinical and utilization 
outcomes.
Conclusions: We observed an overall high usage of high-flow nasal 
oxygen in our cohort of critically ill patients with acute hypoxemic 
respiratory failure secondary to coronavirus disease 2019. Rates of 
endotracheal intubation and mortality in this cohort were on par with 
and certainly not higher than other published series. These findings 
should prompt further considerations regarding the use of high-flow 
nasal oxygen in the management algorithm for coronavirus disease 
2019-associated acute hypoxemic respiratory failure.
Key Words: coronavirus; critical care; high-flow nasal oxygen; 
intubation, intratracheal; noninvasive ventilation; respiratory distress 
syndrome, adult
The role of noninvasive respiratory support strategies in the management of acute hypoxemic respiratory failure (AHRF) secondary to coronavirus disease 2019 (COVID-19) 
is not well defined. Early in the pandemic, anecdotal guidance 
favored early endotracheal intubation, given rapidly escalating 
oxygen requirements seen in infected individuals and concerns 
for viral aerosolization with the use of high-flow nasal oxygen 
(HFNO) or noninvasive positive-pressure ventilation (NIV). As 
international experience with COVID-19 has grown, there have 
been calls for a more nuanced approach to decisions regard-
ing endotracheal intubation, with more consideration given to 
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noninvasive respiratory support strategies early in the disease 
course (1, 2).
The optimal mode of noninvasive respiratory support in 
COVID-19-associated AHRF is unknown. The Society of Critical 
Care Medicine recommends HFNO over NIV for COVID-19-
associated AHRF (3). However, due to lack of data specific to 
COVID-19, this recommendation comes as an extrapolation of 
evidence from other critically ill patient populations. HFNO in 
particular has been shown to be effective in preventing reintuba-
tion in other non-COVID disease states (4, 5) and may even con-
fer a mortality benefit compared with standard oxygen therapy or 
NIV when applied to patients with nonhypercapnic acute respi-
ratory failure (6). Among COVID-19 patients, successful treat-
ment with HFNO and avoidance of intubation has been reported 
among patients with less severe hypoxemia in a small study from 
China (7). Utilization of HFNO, however, appears variable in clin-
ical practice, with only 5% trialed on this modality in a New York 
City COVID-19 cohort and 21% in an early cohort of hospitalized 
patients from Wuhan, China (8, 9). Overall, experiences with use 
of HFNO in COVID-19-associated AHRF have not been exten-
sively described in the literature.
In light of evolving opinion and limited evidence, we sought to 
describe the characteristics and outcomes of adult patients with 
AHRF secondary to COVID-19 who were treated with HFNO as 
a first-line therapy at or near the time of ICU admission.
MATERIAL AND METHODS
This is an observational cohort study of critically ill patients with 
COVID-19-associated AHRF who received HFNO as a first-line 
therapy at or near the time of ICU admission. This cohort was 
screened from a larger cohort of critically ill patients with COVID-
19 who were admitted to nine ICUs (99 beds) at three Thomas 
Jefferson University hospitals in Philadelphia, PA, between March 
18, 2020, and June 3, 2020. All patients had laboratory-confirmed 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
infection via polymerase chain reaction assay of primarily naso-
pharyngeal swabs, with the adjunct of lower respiratory tract 
aspirates, as clinically indicated. During the time of this study, 
all patients were managed under a high-intensity ICU model of 
staffing, irrespective of the unit to which they were admitted (10). 
There were no critical shortages in beds, staffing, ventilators, or 
other supplies.
Patients were included if they received HFNO alone, or HFNO 
in sequential conjunction with NIV delivered by face mask, as a 
first-line therapy at or near the time of ICU admission. The decision 
to initiate HFNO as well as the individual settings of the HFNO 
device (Fisher & Paykel, Auckland, New Zealand, or Vapotherm, 
Exeter, NH) were at the discretion of the attending physician. We 
excluded patients with limitations to their care at ICU admission 
(e.g., do not resuscitate [DNR] and/or do not intubate [DNI]), as 
this may have affected the decision to use noninvasive respiratory 
support strategies. We also excluded patients who received NIV 
alone in our analyses to avoid patients with hypercapnia as the 
primary driver of their respiratory failure. The primary outcome 
of interest was progression to invasive mechanical ventilation. 
Secondary outcomes included ICU and hospital mortalities and 
length of stay (LOS).
Clinical, demographic, and therapeutic data were chart-
abstracted from the electronic medical record and stored in a 
password-protected online data repository, research electronic 
data capture, accessible to key study personnel (11). To compare 
patients who received HFNO alone with those who received 
HFNO in sequential conjunction with NIV, we used chi-square 
or Fisher exact for categorical variables, and Wilcoxon rank-sum 
for continuous variables, as appropriate. A two-sided p < 0.05 was 
considered statistically significant. Statistical analyses were per-
formed with Stata 15.1 (Statacorp, College Station, TX). The study 
was approved by Jefferson’s Office of Human Research Institutional 
Review Board (20E.414) with a waiver of informed consent.
RESULTS
Admission Characteristics
From March 18, 2020, to June 3, 2020, there were 266 admissions 
to the ICU for patients infected with SARS-CoV-2, of which 15 
(5.6%) were nonindex ICU admissions (i.e., readmissions to the 
ICU during the same hospital stay). Overall, 124 (46.6%) of all 
COVID-19 ICU admissions received some form of noninvasive 
respiratory support at the time of or immediately prior to ICU 
admission. After exclusions, we identified 83 patients who were 
treated with HFNO as a first-line therapy, of which 54 received 
HFNO alone and 29 received HFNO in sequential conjunction 
with NIV (Fig. 1).
Patient characteristics of the HFNO cohort are summarized in 
Table 1. Among these 83 patients, the median age was 65 years 
(interquartile range [IQR], 55–76), with 54.2% of patients 65 
years old or older. Patients were predominantly male (63.9%) and 
Black (44.6%). The most common comorbidity was hypertension 
(60.2%), followed by diabetes mellitus (53%). Other chronic ill-
nesses such as malignancy, cerebrovascular accident, and end-
stage renal disease were uncommon. Most patients in the study 
originated from the floor rather than directly from the emergency 
department prior to ICU admission.
The median Acute Physiology and Chronic Health Evaluation 
(APACHE) II score in this cohort was 23 (IQR, 16–30). Nearly 
all patients had inflammatory markers drawn, the median 
peak values of which were elevated far above reference ranges 
(Table 2).
Interventions and Outcomes
Systemic anticoagulation was newly started in 24 patients (28.9%), 
with venous thromboembolic events (i.e., pulmonary embolism or 
deep vein thrombosis) confirmed in six patients (7.2%). Systemic 
steroids were newly administered in 38 patients (45.8%), with the 
predominant indication for steroids being COVID-19 pneumonia 
(22, 57.9%) (Table 2).
Progression to invasive mechanical ventilation was com-
mon and occurred in 58 patients (69.9%) (Table 3). Of these, 30 
(51.7%) were intubated on the same day as ICU admission. The 
median postintubation Pao2:Fio2 ratio was 130 mm Hg (IQR, 97–
210) (Table 2). The median duration on the ventilator was 9 days 
Original Clinical Report
Critical Care Explorations www.ccejournal.org 3
(IQR, 4.5–24.5 d), and tracheostomy was ultimately performed in 
17 patients (29.3%) (Table 3).
As of June 30, 2020, one patient remained admitted to the ICU 
on invasive mechanical ventilation, and six additional patients 
were still hospitalized after leaving the ICU. Among patients with 
available discharge data, ICU mortality was 29.3% (24/82) and 
overall hospital mortality was 32.9% (25/76). The mortality out-
comes of these patients who received HFNO as first-line therapy 
did not differ significantly from those who received no nonin-
vasive respiratory support at or near the time of ICU admission 
(Supplemental Table 1, Supplemental Digital Content 1, http://
links.lww.com/CCX/A387). At the time of death in the ICU, 21 
patients (87.5%) had some form of care limitations (e.g., DNR/
DNI or withdrawal of life support). Median ICU and hospital LOS 
were 9 days (IQR, 4–17 d) and 15 days (IQR, 10–26.5 d), respec-
tively. Among survivors to hospital discharge, the most frequent 
discharge disposition was home (51.0%), followed by acute reha-
bilitation facility (27.5%) (Table 3).
Comparison of HFNO-Alone Group With HFNO + NIV 
Group
We conducted additional analyses to compare the 54 patients who 
received HFNO alone with the 29 patients who received HFNO 
in sequential conjunction with NIV. Demographics were similar 
between the two groups, as were comorbidities, with the exception 
of heart failure, which was more common in the group to which 
NIV was also applied. There was no difference in the median 
APACHE II scores between the two 
groups. Postintubation Pao2:Fio2 
ratios were significantly lower 
among patients who received HFNO 
in conjunction with NIV, and these 
patients were also more likely to 
receive inhaled vasodilator therapy. 
New systemic anticoagulation and 
systemic steroids were administered 
equally between the two groups 
(Table 4).
Neither category of noninva-
sive respiratory support was more 
successful at preventing or delay-
ing endotracheal intubation. 
Furthermore, there was no signifi-
cant difference in the duration of 
invasive mechanical ventilation, tra-
cheostomy rates, ICU and hospital 
mortality, and ICU and hospital LOS 
between the two groups (Table 4).
DISCUSSION
During the initial COVID-19 expe-
rience at our institution, we dem-
onstrated an overall high usage of 
noninvasive respiratory support 
modalities for critically ill patients 
with AHRF secondary to COVID-19. Nearly half of all COVID-19 
ICU admissions received some degree of noninvasive respiratory 
support in the form of HFNO and/or NIV as a first-line therapy, 
and 96 patients (36.1%) were treated, at least in part, with HFNO 
at or near the time of ICU admission.
After exclusions of patients with care limitations, we analyzed 
83 ICU admissions (31.2%), in which HFNO was employed as a 
first-line therapy, alone or in sequential conjunction with NIV via 
face mask. We showed that progression to invasive mechanical 
ventilation was common and occurred early. However, despite a 
high index of illness severity recorded at ICU admission, approxi-
mately two-thirds of patients survived to hospital discharge, and 
among these survivors, over half returned to home. We addition-
ally showed that there were no differences in outcomes among 
patients who received HFNO alone, compared with those who 
received HFNO in sequential conjunction with NIV.
The high utilization rate of HFNO seen in our study dif-
fers considerably from the 5% reported in a New York City ICU 
cohort during their regional peak of the pandemic (8). Similarly, 
in an ICU cohort from Tongji, China, only 10.2% of patients were 
treated with HFNO (12). In Lombardy, Italy, 137 critically ill 
patients (11%) used some form of noninvasive support, although 
it is uncertain where HFNO fell into their care algorithm (13). 
It is possible that the higher HFNO utilization in our cohort is 
explained by the timing of the onset and peak of the pandemic 
in Pennsylvania, which lagged that of China, Italy, and even New 
York by at least a month or more. As such, there may have been 
Figure 1. Patient-selection process. COVID-19 = coronavirus disease 2019, DNI = do not intubate,  
HFNO = high-flow nasal oxygen, NIV = noninvasive positive-pressure ventilation.
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increased comfort with trialing noninvasive respiratory strategies 
due to this delay and, in the setting of absent evidence, a willing-
ness to gauge its impact on patient outcomes.
It remains unknown whether HFNO in COVID-19-associated 
AHRF can prevent progression to invasive mechanical ventila-
tion or affect overall mortality. At our institution, the endotra-
cheal intubation rate for the entire ICU cohort prior to exclusions 
was approximately 70%, which is on the lower end of the 75–88% 
range reported in other published COVID ICU cohorts, both 
domestically and abroad (8, 13–15). In our analyzed cohort of 83 
patients with no care limitations, who received HFNO as a first-
line therapy on ICU admission, the overall endotracheal intuba-
tion rate was 69.9%. Additionally, the ICU mortality rate of 29.3% 
in our cohort of HFNO patients is significantly lower than previ-
ously reported mortality rates, which have ranged from 42.5% to 
78% among other COVID-19 ICU patient cohorts (13, 16, 17). 
The reason for our lower observed rates of endotracheal intuba-
tion without a higher ICU mortality compared with other pub-
lished reports is unclear and may be multifactorial. At the very 
least, our findings are encouraging in that patients with COVID-
19-associated AHRF who received HFNO as a first-line therapy 
did not have worse outcomes. Optimistically, our findings may 
perhaps even suggest that patients with COVID-19-associated 
AHRF who receive HFNO as a first-line therapy may have better 
TABLE 1. Patient Demographic and Admission 
Characteristics
Characteristic (n [%] Unless  
Otherwise Indicated) Total (n = 83)
Age, median (IQR) 65 (55–76)
 Age ≥ 65 45 (54.2)
Male 53 (63.9)
Race
 Black 37 (44.6)
 White 21 (25.3)
 Hispanic 11 (13.3)
 Asian/Pacific-islander 13 (15.7)
 Other/unknown 1 (1.2)
Body mass index, median (IQR) 29.3 (24.9–33.5)
 ≥ 30 kg/m2 36 (43.4)
Smoking status
 Active 5 (6.0)
 Former 35 (42.2)
 Never 36 (43.4)
 Unknown 7 (8.4%)
Comorbidities
 Hypertension 50 (60.2)
 Diabetes mellitus 44 (53.0)
 Congestive heart failure 18 (21.7)
 Chronic obstructive pulmonary disease/
asthma
16 (19.3)
 Coronary artery disease 15 (18.1)
 Cancer 9 (10.8)
 Cerebrovascular accident 7 (8.4)
 End-stage renal disease 5 (6.0)
Nonindex ICU admission 4 (4.8)
Admission source
 Home 64 (77.1)
 Nursing home 14 (16.9)
 Other/unknown 5 (6.0)
Care site immediately prior to ICU
 Floor 47 (56.6)
 Emergency department 27 (32.5)
 Step-down unit 9 (10.8)
Symptom duration prior to presentation (d)
 < 7 40 (48.2)
 7–14 31 (37.3)
 > 14 5 (6.0)
 Unknown 7 (8.4)
IQR = interquartile range.
TABLE 2. Clinical Characteristics and ICU 
Interventions






Acute Physiology and Chronic  
Health Evaluation II score,  
median (IQR)
23 (16–30)  
Laboratory values,a median (IQR)
 Peak d-dimer (ng/mL) 4,502 
(1,946–14,613)
< 230
 Peak C-reactive protein  
(mg/dL)
26.9 (15.6–34.7) ≤ 0.80
 Peak ferritin (ng/mL) 1,375 (763–2,507) 30–400
Pao2:Fio2,
b median (IQR) 130 (97.0–210.5)  
Interventions
 Inhaled pulmonary vasodilator 9 (10.8)  
 New systemic anticoagulation 24 (28.9)  
 New systemic steroids 38 (45.8)  
 New initiation of renal  
replacement therapy
9 (10.8)  
 Prone ventilation 28 (48.3)  
 Extracorporeal membrane  
oxygenation
2 (2.4)  
IQR = interquartile range.
aThree missing values.
bPostintubation values only, two missing values.
cRefers to % proned in 58 mechanically ventilated patients only.
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outcomes than initially expected based on anecdotal guidance 
early in the pandemic. This should prompt clinicians and research-
ers to explore further as to when, for whom, and how HFNO can 
be used in the algorithm for AHRF in COVID-19.
The relative benefits of various noninvasive respiratory sup-
port strategies for the management of (non-COVID-19) AHRF 
have previously been explored. Although the landmark high FLow 
nasal Oxygen in the Resuscitation of patients with Acute Lung 
Injury trial in 2015 popularized the use of HFNO in the treatment 
of AHRF by showing a reduction in 90-day mortality, the primary 
outcome of progression to endotracheal intubation was not sig-
nificantly different between the use of HFNO, NIV, and standard 
oxygen therapy in this study (6). Likewise, other randomized con-
trolled trials exploring whether HFNO can prevent endotracheal 
intubation compared with other noninvasive modalities have 
additionally produced conflicting results (18–22). These vary-
ing findings are likely due to the heterogeneity that exists in the 
underlying etiologies and clinical courses of AHRF, coupled with 
the heterogeneity in the studies comparing various combinations 
of noninvasive respiratory support modalities (e.g., HFNO vs NIV 
via face mask, or HFNO vs standard oxygen therapy) (23). These 
nuances may be especially important to consider with a novel 
respiratory disease such as COVID-19, which may have its own 
unique phenotype(s) (24, 25). Thus, beyond the findings from 
our study, further investigation is warranted to guide clinicians in 
understanding the role of HFNO and/or NIV in potentially delay-
ing or avoiding endotracheal intubation without sacrificing favor-
able patient outcomes.
One major concern among clinicians with using HFNO in 
AHRF secondary to COVID-19 is the possible risk of increased 
aerosolization of viral particles. However, it remains unknown 
how significant this risk may be. At our institution, it is unknown 
whether any cases of healthcare worker infection could be directly 
linked to HFNO exposure. It has been suggested that the aerosol-
ization of respiratory particles with HFNO is similar to that of other 
oxygen support modalities such as a standard oxygen mask (26). 
Similarly, a recent systematic review could not identify demonstra-
tive evidence in either support or rejection of this concern (27). A 
salient risk factor for nosocomial infections of healthcare workers 
described during the current COVID-19 pandemic has included a 
lack of proper personal protective gear, and infections were more 
likely to occur earlier in the pandemic when preparations of per-
sonnel and resources were likely to have been archaic (28). In this 
context, HFNO should continue to be viewed as a viable strategy 
for use in AHRF secondary to COVID-19, but one that needs fur-
ther exploration of the risk-benefit scale in terms of patient out-
comes, local resources, and healthcare worker safety.
Our study has several limitations, including its retrospective 
nature. First, the utilization of HFNO with NIV was not proto-
colized. Although many patients were often stepped-up to NIV 
from HFNO at or near the time of ICU admission, the order and 
duration of use of either modality were at the discretion of the treat-
ing physician. The sequential and alternating use of HFNO and NIV 
has been examined in its ability to affect patient comfort, ventilatory 
parameters, and oxygenation in non-COVID AHRF, but not rates 
of intubation (29). Our descriptive study also precludes conclusions 
about whether their dual use can avoid intubation in some patients. 
Second, our study took place at three hospitals in Philadelphia, PA, 
potentially limiting generalizability to other institutions serving 
patients with differing demographics and socioeconomic vulner-
abilities. Additionally, locoregional differences in the availability 
of personnel and hospital resources could affect viability of using 
HFNO during a pandemic surge. Finally, because our focus was on 
COVID-19 patients with ICU needs, it is possible that more patients 
successfully treated with HFNO were kept on the wards and, there-
fore, were not included in our analyses.
CONCLUSIONS
In our critically ill cohort of patients with AHRF secondary to 
COVID-19, we saw high rates of HFNO utilization, with intuba-
tion and mortality rates that were on par with and certainly not 
higher than other published series. Some have argued that the risk 
of spontaneous respiratory efforts in AHRF may, at times, preclude 
consideration of noninvasive strategies (30). However, the avoid-
ance of invasive mechanical ventilation along with its inherent 
complications is not an unreasonable approach in select patients. 
Our study findings should prompt clinicians and researchers 
to explore further the role of HFNO as a viable strategy in the 
algorithm for COVID-19-associated AHRF. As the decision to 
intubate patients with AHRF is clinical, often based on physician 
judgment, further trials examining the use of HFNO specifically 
in COVID-19 will hopefully provide guidance about the “who, 
when, and how” of using noninvasive respiratory support strate-
gies during this pandemic.
TABLE 3. Clinical Outcomes
Outcome (n [%] Unless Otherwise Indicated) Total (n = 83)
Invasive mechanical ventilation 58 (69.9)
 Time to intubation (d), median (IQR) 0 (0–1)
 Ventilator days,a median (IQR) 9 (4.5–24.5)
 Tracheostomyb 17 (29.3)
ICU mortality 24 (29.3)
Hospital mortality 25 (32.9)
ICU LOS (d),a median (IQR) 9 (4–17)
Hospital LOS (d),c median (IQR) 15 (10–26.5)
Hospital discharge dispositionc,d  
 Home 26 (51.0)
 Long-term acute care 5 (9.8)
 Skilled nursing facility 5 (9.8)
 Rehabilitation facility 14 (27.5)
 Nursing home 1 (2.0)
IQR = interquartile range, LOS = length of stay.
aExcludes one patient still on mechanical ventilation in the ICU as of June 30, 
2020.
bRefers to % tracheostomized in 58 mechanically ventilated patients only.
cExcludes seven patients still hospitalized as of June 30, 2020.
dRefers to disposition among survivors to hospital discharge only.
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TABLE 4. Demographics, Admission and Clinical Characteristics, ICU Interventions, and 
Outcomes for Subgroups




HFNO + Noninvasive  
Positive-Pressure Ventilation
(n = 29) p
Key demographics
Age, median (IQR) 65 (56-78) 67 (53-75) 0.92
Male 33 (61.1) 20 (69.0) 0.48
Race   0.43
 Black 21 (38.9) 16 (55.2)  
 White 15 (27.8) 6 (20.7)  
 Other 18 (33.3) 7 (24.1)  
Body mass index, median (IQR) 28.4 (24.6-32.5) 30.4 (26.3-34) 0.15
Comorbidities    
 Hypertension 32 (59.3) 18 (62.1) 0.80
 Diabetes mellitus 30 (55.6) 14 (48.3) 0.53
 Congestive heart failure 8 (14.8) 10 (34.5) 0.04
 Chronic obstructive pulmonary disease/asthma 8 (14.8) 8 (27.6) 0.16
Key clinical characteristics and ICU interventions
Acute Physiology and Chronic Health Evaluation II score, 
median (IQR)
23 (16–29) 23 (18–33) 0.27
Pao2:Fio2,
a median (IQR) 157 (106-224) 107 (84-183.5) 0.04
Interventions    
 Inhaled pulmonary vasodilator 2 (3.7) 7 (24.1) 0.01
 New systemic anticoagulation 16 (29.6) 8 (27.6) 0.85
 New systemic steroids 21 (38.9) 17 (58.6) 0.09
 New initiation of renal replacement therapy 4 (7.4) 5 (17.2) 0.27
 Prone ventilationb 17 (47.2) 11 (50.0) 0.84
 Extracorporeal membrane oxygenation 1 (1.9) 1 (3.4) 1.00
Key clinical outcomes    
Invasive mechanical ventilation 36 (66.7) 22 (75.9) 0.38
Time to intubation (d), median (IQR) 0.5 (0-1) 0 (0-1) 0.91
Ventilator days,c median (IQR) 8 (4.5-20) 11 (4–30) 0.52
Tracheostomyd 10 (27.8) 7 (31.8) 0.74
ICU mortality 15 (27.8) 9 (32.1) 0.68
Hospital mortalitye 16 (30.8) 9 (37.5) 0.56
ICU LOS,c median (IQR) 8 (4–13) 11.4 (4-19.5) 0.37
Hospital LOS,e median (IQR) 14.5 (9.5-25.5) 19.5 (12-28.5) 0.21
HFNO = high-flow nasal oxygen, IQR = interquartile range, LOS = length of stay.
aPostintubation values only.
bRefers to % proned in 58 mechanically ventilated patients only.
cExcludes one patient still on mechanical ventilation in the ICU as of June 30, 2020.
dRefers to % tracheostomized in 58 mechanically ventilated patients only.
eExcludes seven patients still hospitalized as of June 30, 2020.
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